Henry Schein, Inc. (NASDAQ:HSIC) SVP Sells $1,457,725.50 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) SVP Lorelei Mcglynn sold 21,035 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $69.30, for a total value of $1,457,725.50. Following the completion of the sale, the senior vice president now directly owns 71,833 shares in the company, valued at approximately $4,978,026.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Henry Schein Stock Down 0.7 %

HSIC opened at $67.05 on Thursday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.90 and a current ratio of 1.55. Henry Schein, Inc. has a one year low of $60.01 and a one year high of $82.63. The business’s 50-day simple moving average is $68.99 and its 200-day simple moving average is $70.68. The stock has a market capitalization of $8.50 billion, a P/E ratio of 22.65, a price-to-earnings-growth ratio of 1.93 and a beta of 0.86.

Henry Schein (NASDAQ:HSIC) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $1.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.01. Henry Schein had a net margin of 2.82% and a return on equity of 13.19%. The company had revenue of $3.10 billion for the quarter, compared to the consensus estimate of $3.27 billion. During the same period last year, the firm posted $1.31 EPS. Henry Schein’s revenue for the quarter was up .0% on a year-over-year basis. Analysts anticipate that Henry Schein, Inc. will post 4.75 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on HSIC shares. UBS Group decreased their target price on Henry Schein from $75.00 to $72.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Barrington Research cut their price target on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Piper Sandler restated an “overweight” rating and issued a $86.00 price objective on shares of Henry Schein in a report on Friday, June 21st. Robert W. Baird dropped their target price on Henry Schein from $92.00 to $82.00 and set an “outperform” rating on the stock in a report on Wednesday, August 7th. Finally, Evercore ISI decreased their price target on Henry Schein from $72.00 to $70.00 and set an “in-line” rating for the company in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $77.10.

Institutional Trading of Henry Schein

Several institutional investors and hedge funds have recently added to or reduced their stakes in HSIC. Swedbank AB acquired a new position in shares of Henry Schein in the first quarter valued at approximately $215,998,000. Boston Partners grew its position in Henry Schein by 144.1% in the 4th quarter. Boston Partners now owns 2,637,429 shares of the company’s stock valued at $199,393,000 after buying an additional 1,556,831 shares during the last quarter. Norges Bank acquired a new position in Henry Schein in the 4th quarter valued at $111,715,000. Nuance Investments LLC purchased a new position in Henry Schein during the 4th quarter worth $103,446,000. Finally, Thompson Siegel & Walmsley LLC acquired a new stake in shares of Henry Schein in the 2nd quarter worth $46,683,000. 96.62% of the stock is owned by hedge funds and other institutional investors.

About Henry Schein

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.